Effect of epidural analgesia with ultra-low concentration ropivacaine on inflammatory factors and pregnancy outcomes in parturients with mild preeclampsia: a prospective single-arm clinical trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600122679

Enrollment

Unknown

Registered

2026-04-16

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild preeclampsia

Interventions

Ultra-low concentration ropivacaine epidural analgesia group:Epidural analgesia will be administered with ultra-low concentration (0.0625%) ropivacaine combined with sufentanil. After a loading dose,

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20–40 years, ASA physical status II–III. 2. Diagnosed with mild preeclampsia (systolic blood pressure 140–160 mmHg or diastolic blood pressure 90–110 mmHg, accompanied by proteinuria). 3. Singleton pregnancy, cephalic presentation, term or near-term gestation (> 36 weeks), planned for trial of labor. 4. Cervical dilatation 2–3 cm, with regular uterine contractions and analgesic request (VAS score > 3).

Exclusion criteria

Exclusion criteria: 1. Severe preeclampsia or history of eclampsia. 2. Contraindications to neuraxial anesthesia (e.g., coagulation disorders, infection at the puncture site). 3. History of long-term use of opioids or sedatives. 4. Fetal intrauterine distress.

Design outcomes

Primary

Measure	Time frame
Interleukin-6;Tumor necrosis factor-a;D-dimer;	—

Secondary

Measure	Time frame
Analgesic effectiveness;hemodynamics;degree of motor block;	—

Countries

China

Contacts

Public ContactWu Xizhu

Fujian Maternity and Child Health Hospital

wuxizhu@fjsetyy.com+86 138 5909 4133

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026